GR852858B - - Google Patents

Info

Publication number
GR852858B
GR852858B GR852858A GR850102858A GR852858B GR 852858 B GR852858 B GR 852858B GR 852858 A GR852858 A GR 852858A GR 850102858 A GR850102858 A GR 850102858A GR 852858 B GR852858 B GR 852858B
Authority
GR
Greece
Prior art keywords
difluoronucleosides
mammals
useful
treating neoplasms
neoplasms
Prior art date
Application number
GR852858A
Other languages
Greek (el)
English (en)
Inventor
Gerald Burr Grindey
Larry Wayne Hertel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27101898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR852858(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GR852858B publication Critical patent/GR852858B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GR852858A 1984-12-04 1985-11-27 GR852858B (OSRAM)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67778384A 1984-12-04 1984-12-04
US78641985A 1985-10-10 1985-10-10

Publications (1)

Publication Number Publication Date
GR852858B true GR852858B (OSRAM) 1986-03-28

Family

ID=27101898

Family Applications (1)

Application Number Title Priority Date Filing Date
GR852858A GR852858B (OSRAM) 1984-12-04 1985-11-27

Country Status (21)

Country Link
US (1) US5464826A (OSRAM)
EP (1) EP0184365B1 (OSRAM)
JP (1) JPH0637394B2 (OSRAM)
KR (2) KR890003439B1 (OSRAM)
CN (1) CN1020194C (OSRAM)
AT (1) ATE92499T1 (OSRAM)
AU (1) AU581269B2 (OSRAM)
CA (1) CA1264738A (OSRAM)
CY (1) CY1806A (OSRAM)
DE (1) DE3587500T2 (OSRAM)
DK (1) DK162965C (OSRAM)
EG (1) EG17765A (OSRAM)
ES (1) ES8801546A1 (OSRAM)
GR (1) GR852858B (OSRAM)
HK (1) HK113693A (OSRAM)
HU (1) HU194273B (OSRAM)
IE (1) IE60328B1 (OSRAM)
IL (1) IL77133A (OSRAM)
NZ (1) NZ214364A (OSRAM)
PH (1) PH23172A (OSRAM)
PT (1) PT81559B (OSRAM)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) * 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
RU1787160C (ru) * 1986-12-24 1993-01-07 Эли Лилли Энд Компани Способ получени иммуноглобулинового конъюгата
US4814438A (en) * 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) * 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0306190B1 (en) * 1987-08-28 1998-04-08 Eli Lilly And Company Process for preparing intermediates useful in the preparation of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5644043A (en) * 1988-02-16 1997-07-01 Eli Lilly And Company 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates
IL89258A0 (en) * 1988-02-16 1989-09-10 Lilly Co Eli 2',3'-dideoxy-2',2'-difluoro-nucleosides
US4996308A (en) * 1988-03-25 1991-02-26 Merrell Dow Pharmaceuticals Inc. Derivatives with unsaturated substitutions for the 5'-hydroxymethyl group
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類
CA2004695C (en) * 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
AU4134793A (en) * 1992-06-22 1993-12-23 Eli Lilly And Company 2'-deoxy-2',2'-difluoro(2,6,8-substituted) purine nucleosides having anti-viral and anti-cancer activity and intermediates
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5424416A (en) * 1993-08-25 1995-06-13 Eli Lilly And Company Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
US5480992A (en) * 1993-09-16 1996-01-02 Eli Lilly And Company Anomeric fluororibosyl amines
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5559222A (en) * 1995-02-03 1996-09-24 Eli Lilly And Company Preparation of 1-(2'-deoxy-2',2'-difluoro-D-ribo-pentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro-β-D-ribo-pentopyranose
SK283879B6 (sk) * 1997-01-24 2004-04-06 Conpharma As Deriváty gemcitabínu, spôsob ich prípravy, ich použitie a farmaceutický prostriedok s ich obsahom
AU6473098A (en) * 1997-03-24 1998-10-20 Eli Lilly And Company Difluoronucleoside phosphonic acids and derivatives thereof
TW466112B (en) * 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0019124D0 (en) * 2000-08-03 2000-09-27 Pfizer Novel process
DE60126997T2 (de) * 2000-10-20 2007-10-25 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
US6822001B2 (en) * 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
JP2005513167A (ja) * 2002-01-14 2005-05-12 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体と代謝拮抗剤からなる組合せ
CA2472581C (en) * 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
AU2003217402A1 (en) * 2002-02-14 2003-09-04 Pharmasset Inc Modified fluorinated nucleoside analogues
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004080462A1 (ja) * 2003-03-10 2004-09-23 Eisai Co., Ltd. c-Kitキナーゼ阻害剤
US20080026044A1 (en) * 2003-05-20 2008-01-31 Jonathan Lewis Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex
CA2525952A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising gemcitabine and a liposomal platinum complex
DE10323279A1 (de) * 2003-05-21 2004-12-16 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabin-Lösungen
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
US7683172B2 (en) * 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
DK1711188T3 (da) * 2004-02-06 2012-09-10 Threshold Pharmaceuticals Inc Anticancerterapier
EP2145626A1 (en) * 2004-04-22 2010-01-20 Eli Lilly & Company Combination Therapy for the Treatment of Cancer
KR100578616B1 (ko) * 2004-07-23 2006-05-10 한미약품 주식회사 Ｄ-에리트로-2,2-다이플루오로-2-데옥시-1-옥소라이보스화합물의 제조방법
US8969379B2 (en) * 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US20060089328A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solutions
US20060089329A1 (en) * 2004-10-22 2006-04-27 Edgar Schridde Ready-to-use gemcitabine solution concentrates
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
JP2007522151A (ja) * 2004-12-08 2007-08-09 シコール インコーポレイティド ジフルオロヌクレオシド及びその調製方法
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
TW200637870A (en) 2005-01-31 2006-11-01 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound and salt thereof
GEP20094822B (en) * 2005-03-04 2009-11-10 Dabur Pharma Ltd Intermediate and process for preparing of beta- anomer enriched 21-deoxy, 21, 21-difluoro-d-ribofuranosyl nucleosides
US7485716B2 (en) 2005-05-02 2009-02-03 Pharmaessentia Corp. Stereoselective synthesis of β-nucleosides
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
WO2007023302A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
WO2007052849A1 (ja) * 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
JP5190361B2 (ja) 2006-05-18 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 甲状腺癌に対する抗腫瘍剤
WO2008001956A1 (en) * 2006-06-29 2008-01-03 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
US20100216736A2 (en) 2006-07-21 2010-08-26 Taiho Pharmaceutical Co., Ltd. 2'-cyanopyrimidine nucleoside compound
MX2009001003A (es) 2006-07-24 2009-02-06 Taiho Pharmaceutical Co Ltd Derivado de 3'-etinilcitidina.
CN101511793B (zh) * 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
JP2010510243A (ja) * 2006-11-17 2010-04-02 トラスティーズ オブ ダートマス カレッジ 三環系−ビス−エノン（ｔｂｅ）の合成および生物学的活性
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
EP2116246A1 (en) 2007-01-19 2009-11-11 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
WO2008093855A1 (ja) * 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20090048205A1 (en) * 2007-08-15 2009-02-19 Colin Meyer Combination therapy with synthetic triterpenoids and gemcitabine
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
KR20100102107A (ko) 2007-11-06 2010-09-20 파마이센시아 코퍼레이션 β-뉴클레오시드의 새로운 합성 방법
CN101903396A (zh) * 2007-11-07 2010-12-01 先灵公司 新的细胞周期关卡调节剂和它们与关卡激酶抑制剂的联合应用
EP2218712B1 (en) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EA022166B1 (ru) * 2008-01-11 2015-11-30 Ритэ Фамэсутиклс, Инк. Синтетические тритерпеноиды и их применение в лечении заболеваний
JP5399926B2 (ja) * 2008-01-29 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管阻害物質とタキサンとの併用
MX2010011438A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Antioxidantes moduladores de la inflamacion: derivados del acido oleanólico con amino y otras modificaciones en c-17.
EP2279197B1 (en) 2008-04-18 2014-11-05 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
CN103588678A (zh) 2008-04-18 2014-02-19 里亚塔医药公司 包含抗炎症药效团的化合物以及使用方法
ES2613964T3 (es) 2008-04-18 2017-05-29 Reata Pharmaceuticals, Inc. Moduladores de inflamación antioxidantes: Derivados de ácido oleanólico homologado C-17
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
EP2309860B1 (en) * 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
US8329665B2 (en) * 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
US8329666B2 (en) * 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
US8324180B2 (en) * 2009-04-06 2012-12-04 Eisai Inc. Compositions and methods for treating cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
WO2011021597A1 (ja) 2009-08-19 2011-02-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体含有医薬組成物
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CN102947302A (zh) 2010-02-18 2013-02-27 西班牙国家癌症研究中心 三唑并[4，5-b]吡啶衍生物
EP2547359B1 (en) 2010-03-15 2016-03-09 The Board of Trustees of the University of Illionis Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2011143593A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Conjugates of a lipoic acid derivative and anti-proliferation agent and medical uses thereof
WO2011143590A1 (en) 2010-05-14 2011-11-17 Cornerstone Pharmaceuticals, Inc. Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent
US9192680B2 (en) 2010-06-01 2015-11-24 Aposense Ltd. Pharmaceutical compounds
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
WO2012069972A1 (en) 2010-11-19 2012-05-31 Piramal Life Sciences Limited A pharmaceutical combination for the treatment of breast cancer
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
WO2012123889A1 (en) 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
SG194052A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and erlotinib, and methods of use
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
HRP20181187T1 (hr) 2012-04-04 2018-09-21 Halozyme, Inc. Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
HUE030858T2 (en) 2012-07-04 2017-06-28 Hoffmann La Roche Covalently linked antigen-antibody conjugates
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
WO2014078522A1 (en) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
WO2015191576A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
CA2947504A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
DK3524595T3 (da) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Quinolinderivat af høj renhed og fremgangsmåde til fremstilling deraf
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
CN106317147B (zh) * 2015-07-06 2018-11-27 扬州硒瑞恩生物医药科技有限公司 核苷类化合物及其制备方法
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN109414439A (zh) 2016-06-29 2019-03-01 伊莱利利公司 用于治疗胰腺癌的erk1/2抑制剂化合物与吉西他滨或者与吉西他滨和白蛋白结合型紫杉醇的组合
WO2018094406A1 (en) 2016-11-21 2018-05-24 Bexion Pharmaceuticals, Inc. A combination therapy including sapc-dops for the treatment of pancreatic cancer
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
US20200254037A1 (en) 2017-08-07 2020-08-13 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
FI3826667T3 (fi) 2017-09-18 2024-07-22 Univ California Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
US12480162B2 (en) 2017-10-06 2025-11-25 The Regents Of The University Of Michigan Detection of metastatic disease and related methods
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
MA53140A (fr) 2018-06-29 2021-05-19 Shanghai Changchengyiyaokeji Company Ltd Promédicaments contenant du phosphore de gemcitabine
US20220031670A1 (en) 2018-09-20 2022-02-03 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CA3126211A1 (en) 2019-01-11 2020-07-16 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
FI3941946T3 (fi) 2019-03-20 2025-03-28 Univ California Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja
CN114206934A (zh) 2019-03-20 2022-03-18 加利福尼亚大学董事会 密封蛋白-6双特异性抗体
KR20220002316A (ko) 2019-04-30 2022-01-06 인스티튜토 데 메디시나 몰레큘라 조앙 로보 안투네스 Cdk 억제제와 조합된 rank 경로 억제제
US20220396794A1 (en) 2019-06-04 2022-12-15 Apterna Limited APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
AU2020303986A1 (en) 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
CN110684062B (zh) * 2019-10-18 2022-12-13 大连大学 一种治疗非小细胞肺癌的药物及其制备方法
GB202019692D0 (en) 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (OSRAM) *
US3705147A (en) * 1969-08-22 1972-12-05 Univ Utah 3-deazapyrimidine nucleosides and method of preparation thereof
US3870700A (en) * 1973-05-29 1975-03-11 Miles Lab 2-halogeno-2-deoxy-5-(substituted)uridines
JPS5136467A (en) * 1974-09-20 1976-03-27 Tanabe Seiyaku Co 11 beetaa dd2** harogeno 2** deokishiribofuranoshirurashirujudotai no seiho
DE2628202A1 (de) * 1976-06-23 1977-12-29 Max Planck Gesellschaft Verfahren zur herstellung von 2'-substituierten-d-ribofuranosylpurinderivaten
US4058602A (en) * 1976-08-09 1977-11-15 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ZA859008B (en) * 1984-12-04 1987-07-29 Lilly Co Eli The treatment of tumors in mammals
CA1295998C (en) * 1985-07-29 1992-02-18 Sai P. Sunkara Nucleosides and their use as antineoplastic agents
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US4983724A (en) * 1988-02-16 1991-01-08 Eli Lilly And Company Inversion of 2,2-difluororibose to a 2,2-difluoroxylose and intermediates therefor
JPH0232093A (ja) * 1988-06-08 1990-02-01 Merrell Dow Pharmaceut Inc 抗レトロウィルスジフルオロ化ヌクレオシド類

Also Published As

Publication number Publication date
CN85109409A (zh) 1986-08-27
PH23172A (en) 1989-05-19
CY1806A (en) 1995-09-08
DE3587500D1 (de) 1993-09-09
CN1020194C (zh) 1993-03-31
IE853038L (en) 1986-06-04
ES8801546A1 (es) 1987-08-01
CA1264738A (en) 1990-01-23
HK113693A (en) 1993-10-29
HU194273B (en) 1988-01-28
HUT39188A (en) 1986-08-28
PT81559B (pt) 1988-03-03
EG17765A (en) 1990-08-30
ES549547A0 (es) 1987-08-01
EP0184365A2 (en) 1986-06-11
AU5055585A (en) 1986-06-12
DK549685A (da) 1986-06-05
DE3587500T2 (de) 1993-12-16
NZ214364A (en) 1988-11-29
PT81559A (en) 1985-12-01
EP0184365A3 (en) 1988-01-27
DK162965B (da) 1992-01-06
ATE92499T1 (de) 1993-08-15
KR890003439B1 (ko) 1989-09-21
KR890003426B1 (ko) 1989-09-20
DK549685D0 (da) 1985-11-28
JPH0637394B2 (ja) 1994-05-18
JPS61148193A (ja) 1986-07-05
US5464826A (en) 1995-11-07
KR860004920A (ko) 1986-07-16
IL77133A (en) 1991-01-31
EP0184365B1 (en) 1993-08-04
DK162965C (da) 1992-06-01
AU581269B2 (en) 1989-02-16
IE60328B1 (en) 1994-06-29

Similar Documents

Publication Publication Date Title
GR852858B (OSRAM)
EP0189680A3 (en) Stabilizing power source apparatus
GB8518738D0 (en) Power source
GB2162365B (en) Ion source
GB8601876D0 (en) Treating plastics
JPS57111963A (en) Dc power source
EP0154824A3 (en) Ion source
GB8414113D0 (en) Treating textiles
SG87090G (en) Cascode current source arrangement
GB8525981D0 (en) Treating fabric for shrinkage
GB8515478D0 (en) Light source
GB2156036B (en) Tensioning pulley
GB8519615D0 (en) Treating leather
GB2083954B (en) Improved power source
GB8525642D0 (en) Circulation apparatus
JPS56160798A (en) Dc power source
JPS56159931A (en) Dc power source
GB8419039D0 (en) Ion source
JPS5731340A (en) Dc power source
GB8411587D0 (en) Belt drive arrangement
GB8412753D0 (en) Pulleys
JPS5731339A (en) Dc power source
GB8513300D0 (en) Tensioning means
PL248993A1 (en) Turning over machine for plate-like members
SU1156875A1 (en) Power supply source